IL2 and neoplasm: Our previous preclinical work demonstrated that combining oncolytic adenovirus encoding tumor necrosis factor alpha (TNF) and interleukin-2 (IL-2) with ICI could significantly improve tumor growth control and survival, even in ICI-resistant and refractory settings [11–13].